BioCorRx Inc.

BICX

US09073C2052

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 10:02:39 24/06/2024 pm IST			5-day change	1st Jan Change
0.49 ^USD	-2.00%		-2.00%	-37.18%

15/05	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	BioCorRx Inc. Announces Board Resignations	CI

BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

December 07, 2022 at 07:37 pm IST

BioCorRx Inc. announced that it has partnered with Government Plus LLC to nationally expand its Beat Addiction Recovery Program.

Latest news about BioCorRx Inc.

BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
BioCorRx Inc. Announces Board Resignations	04/04	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	08/02	CI
BioCorRx Inc. Announces President Changes	06/01	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	08/12	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	10/11	CI
Biocorrx Inc. Announces Management Changes	03/11	CI
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/23/15	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Insider Buy: Biocorrx	06/23/06	MT
BioCorRx Inc. announced that it has received $0.299983 million in funding	04/23/04	CI
BioCorRx Inc. announced that it has received $0.599536 million in funding	03/23/03	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
BioCorRx Inc. announced that it expects to receive $0.599536 million in funding	29/23/29	CI
BioCorRx Inc. Announces Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial At 4Th Annual NIH HEAL Initiative Investigator Meeting	08/23/08	CI
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors	24/23/24	CI
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc	19/23/19	CI
BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States	07/22/07	CI
BioCorRx Inc. agreed to Spin-Off BioCorRx Pharmaceuticals, Inc.	22/22/22	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104	13/22/13	CI

BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Sector

Healthcare Facilities & Services

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BIOCORRX INC.	-37.18%	47.3L
HCA HEALTHCARE, INC.	+25.78%	8.94TCr
CVS HEALTH CORPORATION	-23.45%	7.75TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.45%	2.71TCr
LABCORP HOLDINGS INC.	-8.56%	1.75TCr
FRESENIUS SE & CO. KGAA	+0.68%	1.71TCr
QUEST DIAGNOSTICS INCORPORATED	+0.30%	1.56TCr
TENET HEALTHCARE CORPORATION	+78.55%	1.33TCr
NATERA, INC.	+77.76%	1.32TCr
PURE HEALTH HOLDING	-25.61%	1.29TCr

Other Healthcare Facilities & Services

BioCorRx Inc.

Equities

BICX

US09073C2052

Healthcare Facilities & Services

BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

Latest news about BioCorRx Inc.

Chart BioCorRx Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Healthcare Facilities & Services